Adamas Pharmaceuticals (NASDAQ:ADMS) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a sell rating to a hold rating in a report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

A number of other research analysts also recently commented on ADMS. Mizuho reaffirmed a sell rating and issued a $5.00 price target on shares of Adamas Pharmaceuticals in a report on Wednesday, April 24th. HC Wainwright lowered their price target on shares of Adamas Pharmaceuticals from $40.00 to $30.00 and set a buy rating for the company in a report on Tuesday, May 28th. ValuEngine raised shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 1st. Cowen set a $5.00 price target on shares of Adamas Pharmaceuticals and gave the company a hold rating in a report on Friday, August 9th. Finally, Evercore ISI reaffirmed a buy rating and issued a $55.00 price target on shares of Adamas Pharmaceuticals in a report on Monday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $21.81.

ADMS opened at $6.28 on Tuesday. The firm has a 50-day simple moving average of $6.04 and a two-hundred day simple moving average of $6.82. Adamas Pharmaceuticals has a 52 week low of $4.20 and a 52 week high of $23.36. The company has a debt-to-equity ratio of 3.05, a current ratio of 7.27 and a quick ratio of 6.86.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.08. Adamas Pharmaceuticals had a negative net margin of 241.41% and a negative return on equity of 149.97%. The business had revenue of $12.69 million during the quarter, compared to the consensus estimate of $12.62 million. As a group, equities research analysts anticipate that Adamas Pharmaceuticals will post -3.74 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Alps Advisors Inc. raised its position in Adamas Pharmaceuticals by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 66,026 shares of the specialty pharmaceutical company’s stock worth $469,000 after purchasing an additional 2,860 shares during the period. BlackRock Inc. raised its position in Adamas Pharmaceuticals by 9.3% in the 4th quarter. BlackRock Inc. now owns 2,064,758 shares of the specialty pharmaceutical company’s stock worth $17,633,000 after purchasing an additional 174,844 shares during the period. Bingham Osborn & Scarborough LLC raised its position in Adamas Pharmaceuticals by 8.8% in the 1st quarter. Bingham Osborn & Scarborough LLC now owns 145,913 shares of the specialty pharmaceutical company’s stock worth $1,037,000 after purchasing an additional 11,805 shares during the period. Deutsche Bank AG raised its position in Adamas Pharmaceuticals by 506.7% in the 4th quarter. Deutsche Bank AG now owns 274,050 shares of the specialty pharmaceutical company’s stock worth $2,339,000 after purchasing an additional 228,883 shares during the period. Finally, SG Americas Securities LLC raised its position in Adamas Pharmaceuticals by 37.5% in the 1st quarter. SG Americas Securities LLC now owns 33,766 shares of the specialty pharmaceutical company’s stock worth $240,000 after purchasing an additional 9,213 shares during the period. 76.49% of the stock is currently owned by institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Recommended Story: Swap

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.